82720-42-1

Basic information

• Product Name: (4-AMINO-PHENYL)-CARBAMIC ACID BENZYL ESTER
• Synonyms: (4-AMINO-PHENYL)-CARBAMIC ACID BENZYL ESTER;4-(BENZYLOXYCARBONYLAMINO)ANILINE;BENZYL 4-AMINOPHENYLCARBAMATE
• CAS NO: 82720-42-1
• Molecular Formula: C₁₄H₁₄N₂O₂
• Molecular Weight: 242.27
• Mol File: 82720-42-1.mol
• Article Data: 19

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (4-AMINO-PHENYL)-CARBAMIC ACID BENZYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: (4-AMINO-PHENYL)-CARBAMIC ACID BENZYL ESTER(82720-42-1)
• EPA Substance Registry System: (4-AMINO-PHENYL)-CARBAMIC ACID BENZYL ESTER(82720-42-1)

Safety Data

• Hazardous Substances Data: 82720-42-1(Hazardous Substances Data)

Usage

General Description

The chemical compound (4-amino-phenyl)-carbamic acid benzyl ester, also known as benzyl 4-aminophenylcarbamate, is an organic compound with the molecular formula C15H15N2O2. It is a benzyl ester derivative of carbamic acid and is commonly used as a pesticide and a pharmaceutical intermediate. (4-AMINO-PHENYL)-CARBAMIC ACID BENZYL ESTER acts as a carbamate insecticide and a cholinesterase inhibitor, and it has been used in the control of a variety of insect pests, including mosquitoes, flies, and cockroaches. Additionally, (4-amino-phenyl)-carbamic acid benzyl ester has been studied for its potential application as an antihypertensive and anti-thrombotic agent, as well as its use in the treatment of Alzheimer's disease.

Upstream product

• 530-62-1 1,1'-carbonyldiimidazole 
• 106-50-3 1,4-phenylenediamine 
• 100-51-6 benzyl alcohol 
• 13139-17-8 N-(Benzyloxycarbonyloxy)succinimide 
• 220741-56-0 tert-butyl 4-(benzoyloxycarbonylamido)phenylcarbamate 
• 122-80-5 N-acetyl-p-phenylenediamine 
• 501-53-1 benzyl chloroformate 
• 100-01-6 4-nitro-aniline 
• 3422-02-4 N-(benzyloxycarbonyl)aniline 
• 303158-04-5 (4-nitroso-phenyl)-carbamic acid benzyl ester 
• 53821-12-8 benzyl 4-(nitro)phenylcarbamate 

Downstream Products

• 195518-19-5 N-(bromomethyl)-N'-(benzyloxycarbonyl)-phenylenediamine 
• 82734-34-7 2-<4-(benzyloxycarboxamido)phenyl>-2-oxo-1,3,2-dioxaphosphorinane 
• 1450735-84-8 benzyl {4-[(2,4-dihydroxyphenyl)methylidene]-aminophenyl}carbamate 
• 1450735-83-7 benzyl {4-[(4-nitrophenyl)methylidene]aminophenyl}carbamate 
• 1450735-88-2 4-benzyloxycarbonylaminobenzenediazonium p-toluenesulfonate 
• 1402558-55-7 5-(4-aminophenyl)-6,8-dihydrofuro[2,3]pyrrolo[2,4-d]pyrimidin-4-amine 
• 1402558-53-5 benzyl N-[4-(4-amino-6,8-dihydrofuro[2,3]pyrrolo[2,4-d]pyrimidin-5-yl)phenyl]carbamate 

Relevant articles and documents

Design, synthesis and biological evaluation of novel o-aminobenzamide derivatives as potential anti-gastric cancer agents in vitro and in vivo

Although gastric cancer has become a major public health problem, oral agents applied in clinics for gastric cancer therapy are scarce. Therefore, to explore new oral chemical entities with high efficiency and low toxicity, 41 o-aminobenzamide derivatives based on the scaffolds of MS-275 and SAHA were designed, synthesized, and evaluated for their anti-gastric cancer abilities in vitro and in vivo. Structure-activity relationships were discussed, leading to the identification of compounds F8 (IC50 = 0.28 μM against HGC-27 cell) and T9 (IC50 = 1.84 μM against HGC-27 cell) with improved cytotoxicity, anti-gastric cancer proliferation potency, induction of cell apoptosis and cell cycle arrest ability, inhibition of cell migration and invasion. What is worth mentioning is that compound F8 was more efficient and less toxic than the positive drug capecitabine in vivo on the HGC-27-xenograft model. Meanwhile, compound F8 exhibited suitable pharmacokinetic properties and less acute toxicity (LD50 > 1000 mg/kg). Besides, western blotting analysis, IHC analysis, differentially expressed proteins analysis and ABPP experiment indicated that compound F8 could modulate molecular pathways involved in apoptosis and cell cycle progression. Consequently, compound F8 is a strong candidate for the development of human gastric cancer therapy.

COMPOUNDS USEFUL AS CSF1 MODULATORS

This invention relates to novel compounds and to pharmaceutical compositions comprising the novel compounds. More specifically, the invention relates to compounds useful as Colony Stimulating Factor 1 Receptor (cFMS) modulators (e.g. cFMS inhibitors). This invention also relates to processes for preparing the compounds, uses of the compounds in treatment and methods of treatment employing the compounds. Specifically, the invention relates to the use of the compounds for the treatment of cancer and autoimmune diseases.

Chemoselective N-deacetylation under mild conditions

A mild and efficient chemoselective N-deacetylation using the Schwartz reagent at room temperature in rapid time is described. The mild and neutral conditions enable orthogonal N-deacetylation in the presence of some of the common protecting groups (viz. Boc, Fmoc, Cbz, Ts). The deprotection conditions did not induce any epimerization at the chiral amino centre.